DexCom Stock Surges 6.4%, With A 8-Day Winning Spree
DexCom (DXCM) stock hit day 8 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 6.4% return. The company has gained about $1.6 Bil in value over the last 8 days, with its current market capitalization at about $26 Bil. The stock remains 15.6% below its value at the end of 2024. This compares with year-to-date returns of 16.4% for the S&P 500.
DexCom’s recent streak reflects strong market enthusiasm, fueled by the U.S. launch of its extended-wear 15-day G7 continuous glucose monitoring system, offering enhanced accuracy and immediate Medicare coverage. This, coupled with FDA clearance for its innovative Smart Basal insulin dosing optimizer and a Morgan Stanley upgrade to ‘Buy,’ signals robust product momentum and expanding market reach.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades. Our take: There is not much to fear in DXCM stock given its overall Strong operating performance and financial condition. But given its Very High valuation, the stock appears Relatively Expensive (see Buy or Sell DXCM).
For quick background, DXCM provides continuous glucose monitoring systems, including the next-generation G7 CGM, designed, developed, and commercialized for use in the U.S. and internationally.
Comparing DXCM Stock Returns With The S&P 500
The following table summarizes the return for DXCM stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | DXCM | S&P 500 |
|---|---|---|
| 1D | 0.2% | -0.3% |
| 8D (Current Streak) | 6.4% | 1.2% |
| 1M (21D) | 13.1% | 1.9% |
| 3M (63D) | -16.3% | 5.1% |
| YTD 2025 | -15.6% | 16.4% |
| 2024 | -37.3% | 23.3% |
| 2023 | 9.6% | 24.2% |
| 2022 | -15.6% | -19.4% |
However, big gains can follow sharp reversals – but how has DXCM behaved after prior drops? See DXCM Dip Buyer Analysis to learn more.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 53 S&P constituents with 3 days or more of consecutive gains and 104 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 8 | 52 |
| 4D | 22 | 14 |
| 5D | 20 | 6 |
| 6D | 0 | 22 |
| 7D or more | 3 | 10 |
| Total >=3 D | 53 | 104 |
Key Financials for DexCom (DXCM)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $3.6 Bil | $4.0 Bil |
| Operating Income | $597.7 Mil | $600.0 Mil |
| Net Income | $541.5 Mil | $576.2 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $1.0 Bil | $1.2 Bil |
| Operating Income | $133.7 Mil | $212.6 Mil |
| Net Income | $105.4 Mil | $179.8 Mil |
While DXCM stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.